Public Company Information:
SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it will report financial results for the fiscal year ended December 31, 2015 on Wednesday, March 30, 2016. AmpliPhi management will host a conference call at 4:30 pm Eastern Time on March 30, 2016 to review financial results and provide a corporate update.
To access the call, dial 800-895-0198 (US) or 785-424-1053 (outside of the US). The passcode is 9429197. A live webcast will be available in the Events and Presentations section of the Investor Relations page at ampliphibio.com/events-and-presentations. Please log in approximately 10 minutes prior to the scheduled start time.
The archived webcast of the call will be available in the Events and Presentations section of the company's website for 30 days.
About AmpliPhi Biosciences
AmpliPhi Biosciences Corporation (NYSEMKT: APHB) is a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics designed to target infections that are often resistant to existing antibiotic treatments. To advance its pipeline of bacteriophage-based therapies, AmpliPhi is collaborating with a number of leading organizations, including Intrexon Corporation (NYSE: XON), the U.S. Army, The Royal Brompton Hospital in London, UK and UK-based University of Leicester.
Company and Investor relations:
Matt Dansey, +1-858-800-4869
Media relations (USA):
Danielle Lewis/Glenn Silver, + 1-212-867-1762
Media Relations (Europe and ROW):
Gemma Howe/Sue Charles, +44 (0)20 7866 7860